Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Heidelberg, Germany, May 30, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Jefferies 2017 Global Healthcare Conference on Tuesday, June 6, 2017 at 2:00 p.m. (ET) in New York.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]
